Novel peptide may tackle the root cause of type 2 diabetes
British researchers uncover peptide: PEPITEM that could reduce the risk of type 2 diabetes and other obesity-related conditions.
List view / Grid view
British researchers uncover peptide: PEPITEM that could reduce the risk of type 2 diabetes and other obesity-related conditions.
The researchers argue hepatocytes are susceptible to SARS-CoV-2 pseudovirus infection and propose that metformin could be a therapeutic option to attenuate SARS-CoV-2 infection in patients with fatty liver.
US researchers, using genome sequencing, put forward the Nile rat as the new model organism for diabetes research.
German researchers have designed peptides that bind to amyloidogenic proteins linked to Alzheimer’s and type 2 diabetes, to effectively suppress both cytotoxic amyloid aggregation and amyloid cross-accelerating interactions.
Researchers have found that the GDF15 cytokine could have beneficial effects on the metabolism and reduce obesity.
Drug-initiated activity metabolomics screening discovers the metabolite myristoylglycine, that converts white fat cells to brown fat cells.
A capsule that tunnels through mucus in the gastrointestinal tract could be used to orally administer large protein drugs such as insulin.
Researchers have discovered a new pathway to the regeneration of insulin in pancreatic stem cells, findings that could move towards new therapies for type 1 and type 2 diabetes.
In a recent study, scientists have highlighted the possible use of South Asian medicine, specifically, Ayurvedic medicine, to treat type 2 diabetes. In this article, Drug Target Review dives into the study’s implications and what it means for the western world of drug discovery.
A new study led by the Indiana University School of Medicine showed human induced pluripotent stem cells can improve visual acuity, vascular health and other complications related to type 2 diabetes.
A recent pre-clinical study from Washington University School of Medicine showed that a new class of compounds can potentially improve multiple aspects of metabolic syndrome, including diabetes.
Scientists have developed a multi-organoid system from stem cells that can replicate the liver-islet axis in type 2 diabetes.
Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Researchers have revealed that the immune system of obese mice treated with TSLP released lipids through sebaceous glands.